The APA Council on Research has concluded that the current state-of-the-art does not yet support the application of pharmacogenomics in routine clinical practice to predict treatment efficacy in psychiatric disorders.

The APA Council on Research would like to ensure that the Scientific Program Committee is informed of the current limitations in the empirical support for applications of pharmacogenomics in psychiatry.

The APA Council on Research is concerned that companies are marketing pharmacogenomics testing in psychiatry, including at the annual meeting of the APA, in advance of adequate validation of their ability to predict outcome.

In conclusion, the APA Council on Research agrees with the Council on Quality Care that there is insufficient evidence to draft a Resource Document.

1The above response passed with one dissenting vote from Dr. Bankole A. Johnson, who was in favor of the following statement:

“The APA Council of Research is concerned that the current state-of-the-art does not support the application of pharmacogenomics to predict the efficacy of antidepressant treatment for mood and anxiety disorders and suicide prevention.

The APA Council on Research is concerned that companies appear to be marketing pharmacogenomics testing for predicting the efficacy of antidepressants for such disorders in advance of validation by adequately-powered clinical studies or approval by the Food and Drug Administration.

The APA Council on Research agrees with the Council on the Quality of Care that, at this time, there is insufficient evidence to draft a Resource Document but would be willing to commit to a periodic review to provide further guidance to clinicians.”